181 related articles for article (PubMed ID: 37072607)
1. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
[TBL] [Abstract][Full Text] [Related]
2. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
4. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
[TBL] [Abstract][Full Text] [Related]
5. Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.
Fleischmann R; Furst DE; Connolly-Strong E; Liu J; Zhu J; Brasington R
Rheumatol Ther; 2020 Jun; 7(2):327-344. PubMed ID: 32185745
[TBL] [Abstract][Full Text] [Related]
6. Repository Corticotropin Injection (Acthar
Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
[TBL] [Abstract][Full Text] [Related]
7. Repository corticotropin for Chronic Pulmonary Sarcoidosis.
Baughman RP; Sweiss N; Keijsers R; Birring SS; Shipley R; Saketkoo LA; Lower EE
Lung; 2017 Jun; 195(3):313-322. PubMed ID: 28353116
[TBL] [Abstract][Full Text] [Related]
8. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
[TBL] [Abstract][Full Text] [Related]
9. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
Toyos M; Toyos R; Jodoin B; Bunch R
Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497
[TBL] [Abstract][Full Text] [Related]
10. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
[TBL] [Abstract][Full Text] [Related]
11. Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.
Mirsaeidi M; Baughman RP
Pulm Ther; 2022 Mar; 8(1):43-55. PubMed ID: 35113366
[TBL] [Abstract][Full Text] [Related]
12. Understanding Predictors of Response to Repository Corticotropin Injection Treatment Among Patients With Advanced Symptomatic Sarcoidosis.
Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio MP; Wan GJ
J Health Econ Outcomes Res; 2022; 9(1):90-100. PubMed ID: 35529249
[No Abstract] [Full Text] [Related]
13. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
14. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.
Chopra I; Qin Y; Kranyak J; Gallagher JR; Heap K; Carroll S; Wan GJ
Ther Adv Respir Dis; 2019; 13():1753466619888127. PubMed ID: 31722624
[TBL] [Abstract][Full Text] [Related]
15. Repository corticotropin injection (H.P. Acthar gel) for the treatment of sarcoidosis-induced hypercalciuria and vitamin D dysregulation: a pilot, open label study.
Judson MA; Modi A; Ilyas F; Yucel R
Sarcoidosis Vasc Diffuse Lung Dis; 2018; 35(3):192-197. PubMed ID: 32476902
[No Abstract] [Full Text] [Related]
16. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.
Furie R; Mitrane M; Zhao E; Das M; Li D; Becker PM
Lupus Sci Med; 2016; 3(1):e000180. PubMed ID: 27933199
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
Kaplan J; Miller T; Baker M; Due B; Zhao E
Front Neurol; 2020; 11():598496. PubMed ID: 33414758
[No Abstract] [Full Text] [Related]
19. Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis.
Fleischmann R; Hayes K; Ahn SW; Wan GJ; Panaccio M; Karlsson D; Furst DE
Rheumatol Ther; 2022 Apr; 9(2):649-661. PubMed ID: 35184268
[TBL] [Abstract][Full Text] [Related]
20. Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis.
Fleischmann R; Furst DE
Expert Opin Drug Saf; 2020 Aug; 19(8):935-944. PubMed ID: 32497440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
